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S U M M A R Y
Objectives: Crimean-Congo hemorrhagic fever (CCHF) is a lethal hemorrhagic disease. There is currently
no speciﬁc antiviral therapy for CCHF approved for use in humans. In this study we aimed to investigate
the effect of oral ribavirin treatment on the viral load and disease progression in CCHF.
Methods: The study population was composed of patients who had a deﬁnitive diagnosis of CCHF by
means of clinical presentation plus detection of viral RNA by reverse transcriptase polymerase chain
reaction (RT-PCR). Ten patients who received oral ribavirin for 10 days and 40 control patients who
received supportive treatment only were included in the study. Ribavirin treatment consisted of oral
ribavirin 4 g/day for 4 days and then 2.4 g/day for 6 days. Viral load and hematological and biochemical
laboratory parameters, which were measured daily, were analyzed.
Results: Mean age (37.4 vs. 45.5, p = 0.285), gender (male 50% vs. 62.5%, p = 0.470), days from the
appearance of symptoms to admission (4.3 vs.4.4 days, p = 0.922), and initial complaints were similar
between the ribavirin group and the control group. Upon hospital admission, mean viral load was
8.2  108 copies/ml in the ribavirin group and 8.3  108 copies/ml in the control group (p = 0.994).
During follow-up, no statistically signiﬁcant differences were found between the groups with regard to
the decrease in viral load, the reduction in alanine aminotransferase and aspartate aminotransferase
levels, and the increase in platelet count. The case-fatality rate was 20% (2/10 patients) in the ribavirin
group and 15% (6/40 patients) in the control group (p = 0.509).
Conclusion: In this study, oral ribavirin treatment in CCHF patients did not affect viral load or disease
progression.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Crimean-Congo hemorrhagic fever (CCHF) is a potentially fatal
infection causedby the CCHFvirus belonging to the genusNairovirus
of the family Bunyaviridae. The CCHF virus is transmitted to humans
by Hyalomma ticks or by direct contact with the blood of infected
humans or domestic animals.1 Presently, CCHF is a public health
problem inmore than 30 countries in Africa, Asia, Southeast Europe,
and the Middle East.2,3 Since 2002, a rapid emergence of CCHF has
occurred in thecentral, northern,andeastern regionsofTurkey.4,5By
the end of 2007, there had been 1820 conﬁrmed cases and 92deaths
(a case-fatality rate of 5%) in Turkey.6
Treatment options for CCHF are limited. There is currently no
speciﬁc antiviral therapy for CCHF approved for use in humans.1* Corresponding author. Tel.: +90 312 5084840.
E-mail address: hurrembodur@gmail.com (H. Bodur).
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ribavirin as a potential therapeutic drug for CCHF.3,7 Ribavirin has
been found to be effective against CCHF virus in vitro,8,9 but the
efﬁcacy of ribavirin remains controversial.10,11
For many viral diseases, including CCHF, viral load measure-
ment has become an important part of disease management.
Furthermore, increased severity of the CCHF disease has been
shown to correlate with high viremia titers.12,13
In this study, we aimed to investigate the effect of oral ribavirin
treatment on the viral load and disease progression in CCHF
patients in Turkey.
2. Materials and methods
2.1. Patient population
This case–control study was conducted at the Ankara Numune
Education and Research Hospital between 2006 and 2008. Theses. Published by Elsevier Ltd. All rights reserved.
Table 1
Comparison of baseline characteristics and laboratory ﬁndings between the ribavirin group and the control group
Characteristic Ribavirin group (n=10) Control group (n=40) p-Value
Age, years 37.417.9 45.519.3 0.285a
Male sex 5 (50%) 25 (62.5%) 0.470b
Duration of complaints until hospitalization, days 4.31.4 4.41.4 0.922a
Most common complaints
Myalgia 10 (100%) 37 (92.5%) 0.504c
Fever 10 (100%) 38 (95%) 0.637c
Lack of appetite 10 (100%) 38 (95%) 0.637c
Headache 9 (90%) 31 (77.5%) 0.349c
Nausea and/or vomiting 8 (80%) 25 (62.5%) 0.257c
Bleeding (any kind) 3 (30%) 14 (35%) 0.539c
Physical ﬁndings
Fever, temperature >38 8C 4 (40%) 19 (47.5%) 0.670c
Hepatomegaly 0 (0%) 3 (7.5%) 0.504c
Splenomegaly 1 (10%) 1 (2.5%) 0.363c
Rash
Maculopapular 1 (10%) 7 (17.5%) 0.491c
Petechiae 3 (30%) 7 (17.5%) 0.314c
Bleeding
Ecchymosis 2 (20%) 7 (17.5%) 0.584c
Epistaxis 2 (20%) 9 (22.5%) 0.618c
Hematemesis 2 (20%) 3 (7.5%) 0.258c
Melena 0 (0%) 5 (12.5%) 0.311c
Somnolence 2 (20%) 5 (12.5%) 0.429c
Laboratory ﬁndings
Platelet count ( 109/l) 52.847.5 58.141.3 0.544d
WBC count ( 109/l) 2.3201.203 2.7071.210 0.444d
AST level, U/l (normal range 5–34 U/l) 305280 336331 0.780d
ALT level, U/l (normal range 0–55 U/l) 13392 166214 0.560d
LDH level, U/l (normal range 123–243 U/l) 737439 649416 0.559d
CPK, U/l (normal range 25–200 U/l) 512401 9181044 0.525d
PT, s (normal range 11.5–15.5 s) 12.42 12.72 0.653a
aPTT, s (normal range 20–34 s) 42.819.5 40.915 0.971d
INR (normal range 0.8–1.2) 0.980.16 1.020.16 0.551a
Fibrinogen, mg/dl (normal range 180–350 mg/dl) 25174 26473 0.734d
Data are n (%) of patients or mean value standard deviation.
WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CPK, creatine phosphokinase; PT, prothrombin time; aPTT,
activated partial thromboplastin time; INR, international normalized ratio.
a Student’s t-test.
b Chi-square test.
c Fisher’s exact test.
d Wilcoxon–Mann–Whitney test.
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diagnosis of CCHF by means of clinical presentation plus detection
of viral RNA by reverse transcriptase polymerase chain reaction
(RT-PCR). Patients with suspected cases of CCHF were offered oral
ribavirin therapy upon hospital admission. Ribavirin treatment
was initiated before laboratory conﬁrmation of the CCHF diagnosis,
as the results were only available a few days after obtaining the
samples. If a patient agreed to use ribavirin treatment, they were
treated with oral ribavirin 4 g/day for 4 days and then 2.4 g/day for
6 days. Only ribavirin-treated patients with a conﬁrmed CCHF
diagnosis by RT-PCR were included in the study. Control patients
received supportive treatment only. All patients also received
preparations of erythrocytes, platelets, and fresh frozen plasma,
depending on their homeostatic state.
In total, this study included 10 case patients (patients who
received oral ribavirin) and 40 control patients (patients who
received supportive treatment only). For each ribavirin case, four
control cases were randomly selected to match one ribavirin case
with respect to similar initial viral loads and duration of symptoms.
Matching ribavirin and control cases in a 1:4 ratio maximized the
power of the analysis.
Written informed consentwas obtained from the patient and/or
their family members for all patients enrolled in this study. Also,
for each patient, permission was obtained from the TurkishMinistry of Health to use ribavirin for an unlicensed indication.
This study also followed procedures in accordance with the ethical
standards of the Helsinki Declaration.
2.2. Laboratory assessments
Quantitative measurements of CCHF virus were performed
daily. A TaqMan-based one-step RT-PCR assay was used for
detection and quantiﬁcation of CCHF virus RNA.14 The assay was
performed in a Perkin-Elmer 7700 Sequence Detection System by
using the combination of reverse-transcriptase (MBI Fermentas)
and Hot Start Taq DNA Polymerase (Birion GmBH) enzymes.
Biochemical and hematological laboratory parameters were
measured on a daily basis after hospital admission.
2.3. Statistical analysis
Viral loads and hematological and biochemical laboratory
parameters, measured on a daily basis, were analyzed. Patient
outcomes were also analyzed. The Chi-square test or Fisher’s exact
test was used when appropriate to compare proportions.
Continuous variables were compared using an independent-
groups t-test if normality assumptions were met; otherwise
groups were compared using the Wilcoxon–Mann–Whitney test.
Table 2
Comparison of the duration of hospitalization, amounts of administered blood products, and outcome between the ribavirin group and the control group
Characteristic Ribavirin group (n=10) Control group (n=40) p-Value
Duration of hospitalization (days) 6.62.8 7.42.5 0.398a
Mean thrombocyte suspension transfused (units) 26.317.7 29.314.6 0.616b
Mean fresh frozen plasma transfused (units) 20.413.3 15.213.9 0.239b
Mean erythrocyte suspensions transfused (units) 21.8 2.631.8 0.791b
Fatal outcome 2 (20%) 6 (15%) 0.509c
a Student’s t-test.
b Wilcoxon–Mann–Whitney test.
c Fisher’s exact test.
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Figure 1. Ribavirin effect on viral load over time; p > 0.05 (data were log-
transformed).White dots represent the ribavirin group and black dots represent the
control group.
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quadratic growth curve mixed effects model was performed. Daily
viral load data were log-transformed to meet the normality
assumption for use in the quadratic growth curve mixed effects
model. p-Values of <0.05 were considered to be statistically
signiﬁcant. Software package Stata 9.0 (Stata Corp., College station,
TX, USA) was used for the analysis.
3. Results
Between 2006 and 2008, 188 patients were diagnosed with
CCHF and 141 of them had PCR results positive for CCHF virus RNA
in blood samples. Quantitative measurement of CCHF virus was
performed daily in 109 patients. Among these patients, 10who had
received oral ribavirin and 40 controls who had received
supportive treatment only were included in the study.
Baseline clinical characteristics and laboratory values of the
ribavirin and control groups are presented in Table 1, which shows
that both groups had similar baseline and laboratory test results
upon admission.
The efﬁcacy of ribavirin therapy was evaluated with respect to
viral load, supportive treatment required by the patients during
the course of the disease, mean duration of hospitalization, and
fatal outcome between the ribavirin group and the control group.
No statistically signiﬁcant differences between the two groups
were determined for any of these parameters (Table 2).
Erythrocyte suspension infusions were needed in 40% and 20%
(p = 0.186), fresh frozen plasma in 50% and 42.5% (p = 0.669), and
platelet suspension in 60% and 45% (p = 0.396) of those in the
ribavirin group and the control group, respectively. The quantities
of blood or blood product infusions required per patient are
compared in Table 2. Although the amount of fresh frozen plasma
administered per patient was lower in the control group, amounts
of other blood productswere similar and no statistically signiﬁcant
differences were found.
No statistically signiﬁcant difference was found between the
ribavirin and control groups during daily follow-up with regard to
the decrease in viral load, the reduction in alanine aminotransfer-
ase (ALT) and aspartate aminotransferase (AST) levels, and the
increase in platelet count (Figure 1).
At the time of hospital admission, viral loads ranged from
1  103 to 9.9  109 copies/ml in the serum samples. The mean
viral load was 8.2  108 copies/ml (range 8.4  103–7.2  109) in
the ribavirin group and 8.3  108 copies/ml (range 6.1  103–
9.9  109) in the control group (p = 0.994). Viral loads of 1  109
copies/ml were detected in one patient in the ribavirin group and
in four patients in the control group. All of these patients had fatal
outcomes. Furthermore, two patients in the control group and one
patient in the ribavirin group had viral loads 5.5  108 copies/ml
at admission. One of these control patients had a viral load of
5.5  108 copies/ml at admission, which was elevated to 3.9  109
copies/ml on the third day of hospitalization.With the exception of
one control patient with a non-fatal outcome and a titer of7.5  108 copies/ml at admission, all patients with fatal outcomes
had viral loads 5.5  108 copies/ml at the time of hospital
admission.
The number of patients with a positive viral load on each day
over the total number tested for viral load in the ribavirin group
and control group, respectively, were as follows: ﬁrst day 10/10
and 40/40, second day 9/10 and 30/39, third day 5/9 and 22/39,
fourth day 2/9 and 12/37, ﬁfth day 1/9 and 4/34, and sixth day 1/8
and 0/34 (patients with negative viral loads were included in the
analysis and patients who died were excluded from the analysis).
In patients with fatal outcomes, the mean duration of
symptoms before hospitalization was 4.5  0.7 days in the ribavirin
group and 4.2  0.9 days in the control group (p = 0.680). The case-
fatality rate was 20% (2/10 patients) in the ribavirin group and 15% (6/
40 patients) in the control group (p = 0.509; Table 2).
4. Discussion
Treatment for CCHF is primarily supportive.1,3 Ribavirin has
been used in the treatment of CCHF, but its efﬁcacy in the
treatment of this disease is controversial.10,11,15–17 Ribavirin is a
guanosine analog with a broad spectrum of activity in vitro against
RNA viruses, and it has been shown to inhibit viral replication of
the CCHF virus in vitro.8,9,18,19
The level of viremia has been shown to have prognostic
signiﬁcance in CCHF, and the duration of symptoms has been
shown to have a signiﬁcant effect on the disease stage. A high viral
load tends to indicate a fatal outcome, and thus viral load is a useful
predictor of clinical progress.12,13 Speciﬁcally, a viral load of 108
copies/ml is a strong factor for differentiating CCHF patients who
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systematic monitoring of patients receiving ribavirin therapy.20
There are several case reports and observational studies on the
efﬁcacy of ribavirin in CCHF.10,11,15–17 The shared features of these
observational studies are small sample sizes, retrospective nature,
and, in most of them, unknown disease severity. These observa-
tional studies show conﬂicting results with regard to the efﬁcacy of
ribavirin. However, to date, no randomized controlled studies have
been performed to rigorously conﬁrm the efﬁcacy of ribavirin for
treating CCHF.
In order to investigate the effect of oral ribavirin treatment on
viral load, we chose to perform a case–control study. As severity
and stage of the disease and different time delays before
treatment can affect the progression of CCHF, we randomly chose
four control patients for each ribavirin-treated patient with the
same viral load and the same duration of symptoms in order to
prevent potential selection bias while composing the study
groups.
There are some limitations to our study. Our sample size was
small, as the study group consisted of 50 patients and there were
only 10 patients in the ribavirin treatment group. A further
limitation was the retrospective nature of the data collection.
In our study, comparison of baseline characteristics of the
patients showed that both groups had similar ﬁndings and similar
laboratory test results at admission. A quadratic growth curve
mixed effects model was performed in order to compare the effect
of ribavirin on viral load between the two groups simultaneously
over time. There was no signiﬁcant effect of ribavirin on the
decrease in viral load. At follow-up, the decrease in ALT and AST
levels and the increase in platelet count did not show any
statistically signiﬁcant difference on a daily basis between the
ribavirin and control groups. The mean duration of hospitalization
was 6.6 days in the ribavirin group and 7.4 days in the control
group (p = 0.398). The case fatality rate was 20% in the ribavirin
group and 15% in the control group (p = 0.509). All fatal cases had a
viral load 5.5  108 copies/ml at admission, regardless of
ribavirin use.
In conclusion, oral ribavirin treatment in CCHF did not show any
effect on viral load or the disease progression in this study. It is very
difﬁcult to reach a consensus about the efﬁcacy of ribavirin in the
treatment of CCHF with these conﬂicting results in the literature.
Therefore, this highlights the need for randomized controlled trials
with larger sample sizes.
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